Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2Papillomavirus Infections 1Osteoporosis 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Inflammatory Bowel Diseases 1Infertility 1High Grade Cervical Intraepithelial Neoplasia 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 35Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 23Papillomavirus Vaccines 14Data Collection 7Blood Specimen Collection 7Vaccines 6Vaccines, Synthetic 5Educational Status 5Radiotherapy, Intensity-Modulated 4Human Papillomavirus Recombinant Vaccine nonavalent 4Early Intervention, Educational 4Vaginal Smears 3Surveys and Questionnaires 3Polymerase Chain Reaction 3Paclitaxel 3Methods 3Engerix-B 3Colposcopy 3Cisplatin 3halofantrine 2fludarabine phosphate 2fludarabine 2aldesleukin 2Watchful Waiting 2Taxes 2Patient Navigation 2Papanicolaou Test 2Observation 2Light Coagulation 2Imiquimod 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Papillomavirus Infections × Biological Products × Clear all
NCT04436133 2022-05-06

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

National Vaccine and Serum Institute, China

Phase 2 Completed
480 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡